Introduction
The European Network for Health Technology Assessment (EUNetHTA) is a pan‑European collaboration that aims to improve the quality, relevance, and impact of health technology assessment (HTA) across member states. Founded in the early 2000s, the network serves as a platform for exchange of knowledge, harmonisation of methods, and joint research initiatives among national HTA organisations, academic institutions, and industry stakeholders. Its core mission is to support decision‑making processes concerning the adoption, reimbursement, and use of health technologies within the European Union (EU) and beyond.
Health technology assessment is an interdisciplinary field that evaluates the clinical effectiveness, cost‑effectiveness, ethical, social, and organisational implications of health technologies. Within the EU, national HTA bodies conduct assessments to inform policy decisions on medicines, medical devices, diagnostics, and other interventions. EUNetHTA was created to address the fragmentation and duplication of efforts across national HTA organisations, to promote methodological consistency, and to facilitate timely access to high‑quality evidence for decision makers.
Over its lifespan, EUNetHTA has evolved from a research collaboration into a more structured partnership with established governance, funding mechanisms, and a portfolio of joint projects. The network has contributed to the development of European guidelines, best‑practice documents, and training programmes that influence HTA practice not only in Europe but also in other regions that emulate European models.
History and Background
Early Foundations
The seeds of EUNetHTA were planted in the late 1990s, when several European national HTA agencies recognised the need for a coordinated approach to knowledge sharing. At that time, health technology assessment was still emerging as a formal field in many countries, and national agencies operated largely in isolation. In 2000, a series of workshops convened by the European Commission’s Directorate-General for Health and Consumers highlighted the potential benefits of a networked structure. These workshops laid the groundwork for what would become EUNetHTA.
In 2001, the European Commission funded a pilot project titled “European Network for Health Technology Assessment: Harmonisation of HTA Practices.” This project involved 15 national HTA organisations and produced initial recommendations on methodological standardisation and collaborative frameworks. The success of this pilot prompted the Commission to support a formal establishment of the network in 2003.
Formal Establishment (2003–2006)
In 2003, EUNetHTA was officially launched during a meeting in Brussels. The initial steering committee comprised representatives from the national HTA agencies of France, Germany, Italy, the Netherlands, Spain, and the United Kingdom. The network adopted a constitution that defined its objectives, membership criteria, and governance structure. Membership was initially limited to national HTA bodies, but the constitution also allowed for participation of academic institutions, patient groups, and industry stakeholders on an associate basis.
Between 2003 and 2006, EUNetHTA focused on developing a common methodological framework. This effort culminated in the publication of the “European Guideline for Health Technology Assessment” (EUNetHTA Guideline) in 2006, which provided detailed guidance on assessment design, data collection, economic evaluation, and reporting standards. The guideline has since become a reference document for national HTA agencies and has influenced the development of similar guidelines in other regions.
Expansion and Consolidation (2007–2015)
During this period, EUNetHTA broadened its membership to include 20 national HTA organisations and several European research institutions. The network also began to address emerging areas of health technology, such as digital health, personalised medicine, and complex interventions. Collaborative projects were launched to evaluate these technologies across multiple jurisdictions, thereby generating evidence that could be reused by national agencies.
A key milestone was the establishment of the EUNetHTA Repository in 2009, a digital platform that houses published HTA reports, methodological guidelines, and data sets. The repository facilitates knowledge transfer and reduces duplication of effort by providing a single access point for high‑quality HTA outputs.
Modern Era and EU Integration (2016–Present)
In 2016, the European Commission integrated EUNetHTA into the broader European Health and Care Services (EHC) initiative. This integration reinforced the network’s role in shaping EU‑level health policy and in contributing to the development of the European Health Data Space. Funding mechanisms evolved to include a combination of Commission grants, national contributions, and in‑kind support from member organisations.
Recent years have seen EUNetHTA tackle global challenges such as the COVID‑19 pandemic, antimicrobial resistance, and the rise of artificial intelligence in health care. The network has coordinated rapid assessment programmes to evaluate vaccines, therapeutics, and diagnostic tools, providing timely evidence to policymakers across Europe.
Organisational Structure
Governance
EUNetHTA operates under a multi‑layered governance model designed to balance representation, expertise, and operational efficiency. The highest decision‑making body is the Annual General Meeting (AGM), which convenes each year and includes all full members. The AGM approves the annual budget, strategic priorities, and major initiatives.
Beneath the AGM is the Executive Committee, comprising chairpersons from each full member country. The Executive Committee meets quarterly to oversee project implementation, resolve conflicts, and provide guidance on methodological issues.
The Secretariat, located in Brussels, manages day‑to‑day operations, coordinates communication among members, and ensures compliance with funding requirements. The Secretariat is staffed by a team of senior analysts, project managers, and administrative personnel.
Membership Categories
- Full Members: National HTA organisations that meet the criteria of independence, expertise, and financial contribution. Full members have voting rights in the AGM and Executive Committee.
- Associate Members: Academic institutions, patient organisations, and industry representatives that contribute expertise or data. Associates can participate in projects but do not hold voting rights.
- Collaborating Partners: Organisations that provide in‑kind support, such as software tools or data repositories. Collaborators can be engaged on specific projects but are not part of governance.
Funding Model
Funding for EUNetHTA originates from three primary sources:
- European Commission Grants: Large‑scale projects aligned with EU policy objectives receive funding through Horizon Europe or similar programmes.
- National Contributions: Each full member contributes a percentage of its annual HTA budget, typically calculated on a proportional basis.
- In‑Kind Donations: Associates and collaborators may provide software, data, or personnel time, reducing operational costs.
Key Activities and Projects
Methodological Harmonisation
EUNetHTA maintains a set of core methodological standards that are applied across member organisations. These standards cover clinical effectiveness, economic evaluation, health‑related quality of life measurement, and societal impact assessment. The network publishes a biennial methodological review that updates guidelines to reflect advances in health economics and epidemiology.
Joint Assessment Projects
One of the network’s flagship initiatives is the Joint Assessment Programme (JAP), which conducts multinational HTA studies on health technologies that are likely to be used across several EU member states. By sharing data, expertise, and analytical frameworks, the JAP reduces duplication and accelerates the availability of assessment results.
Examples of JAP projects include:
- Vaccines: Comparative effectiveness studies of new influenza and COVID‑19 vaccines across 12 European countries.
- Digital Therapeutics: Assessment of mobile‑based interventions for type 2 diabetes management in 8 member states.
- Rare Disease Therapies: Economic evaluations of orphan drugs for cystic fibrosis and spinal muscular atrophy.
Capacity Building and Training
EUNetHTA organizes a range of training programmes, workshops, and fellowship opportunities aimed at building HTA capacity across Europe. These programmes target a diverse audience, including researchers, clinicians, health economists, and policy analysts. Notable training initiatives include:
- Summer School in Health Technology Assessment: An intensive 2‑week course covering methodological foundations, case studies, and policy implications.
- Mentorship Scheme: Pairing early‑career researchers with senior HTA experts for guidance on project design and publication.
- Online Modules: Self‑paced courses on topics such as cost‑effectiveness analysis, decision modelling, and data extraction.
Evidence Repositories and Data Sharing
The EUNetHTA Repository hosts a comprehensive catalogue of HTA reports, systematic reviews, data sets, and methodological tools. Access to the repository is free for member organisations and is subject to a licensing agreement for non‑members. The repository employs metadata standards that enable efficient search and retrieval of documents.
Additionally, the network maintains the EUNetHTA Data Hub, a secure platform that facilitates the sharing of patient‑level data for pooled analyses. The Data Hub operates under strict privacy regulations and allows members to conduct joint meta‑analyses without disclosing raw data.
Rapid Assessment Response
In response to public health emergencies, EUNetHTA can mobilise a Rapid Assessment Team (RAT). The RAT is composed of experts from multiple disciplines who conduct expedited assessments of emerging health technologies. The RAT’s outputs inform emergency response plans, procurement decisions, and reimbursement policies during crises such as pandemics.
Impact and Contributions
Policy Influence
By providing harmonised evidence, EUNetHTA has influenced national reimbursement policies across Europe. Several member countries have adopted joint assessment findings as a basis for coverage decisions, thereby ensuring consistency in access to high‑quality therapies. The network’s methodological guidelines are also referenced in European Commission policy documents on health technology regulation.
Research Advancement
EUNetHTA’s collaborative projects have resulted in a substantial body of peer‑reviewed literature. Joint assessments are often published in high‑impact journals, contributing to the global evidence base on health technology performance. Moreover, the network’s emphasis on methodological rigour has spurred methodological innovations, such as the adoption of real‑world evidence and network meta‑analysis techniques.
Standardisation of Terminology
Through its Glossary of HTA Terms and Definitions, EUNetHTA has promoted a common lexicon across European HTA organisations. This standardisation reduces misunderstandings and facilitates cross‑border collaboration on research and policy initiatives.
Economic Efficiency
By reducing duplication of assessments and fostering data reuse, EUNetHTA contributes to cost savings for national HTA bodies. The network’s joint projects often require only a fraction of the resources that would be necessary if each country conducted separate assessments. These efficiencies enable member organisations to allocate resources to other priority areas such as capacity building and stakeholder engagement.
Criticisms and Challenges
Methodological Diversity
Despite efforts at harmonisation, methodological differences persist among national HTA bodies. Variations in modelling techniques, cost perspectives, and health outcome measures can still lead to divergent conclusions. Critics argue that the network’s guidelines, while comprehensive, are sometimes too broad to be applied uniformly, leading to inconsistencies in assessment quality.
Resource Constraints
While the joint assessment model reduces duplication, it also places significant demands on a core group of experts who must manage large, multinational projects. Resource constraints, including limited staffing and funding volatility, can impede the timely delivery of joint assessments.
Stakeholder Representation
The governance structure, which is dominated by national HTA agencies, has been criticised for limited direct input from patient groups and other non‑governmental stakeholders. Some argue that patient‑centred outcomes and societal preferences are under‑represented in joint assessment processes.
Data Privacy and Governance
The sharing of patient‑level data across borders raises concerns about data privacy, especially in the context of varying national data protection laws. Although the Data Hub implements robust security measures, disagreements over data governance can delay collaborative analyses.
Transparency and Accountability
Transparency in decision‑making processes and funding allocation remains a concern for some observers. Critics point to a lack of public reporting on the network’s internal deliberations and the criteria used to select joint projects.
Future Directions
Digital Health and AI Integration
EUNetHTA plans to expand its focus on digital health technologies and artificial intelligence (AI) applications. This includes developing specific guidelines for the assessment of AI‑driven diagnostics, predictive analytics, and personalised medicine platforms. The network aims to incorporate real‑world data and machine‑learning techniques into assessment frameworks.
Global Partnerships
To extend its impact beyond Europe, EUNetHTA seeks to establish formal collaborations with HTA bodies in other regions such as the United Kingdom (post‑Brexit), Canada, Australia, and Japan. These partnerships would facilitate the exchange of best practices and potentially harmonise assessment standards on a global scale.
Enhanced Patient Involvement
Future initiatives include mechanisms for systematic patient and public engagement in joint assessment projects. This may involve patient advisory panels, co‑design of research questions, and integration of patient‑reported outcome measures into assessment reports.
Data Governance Frameworks
To address privacy concerns, EUNetHTA is working on a comprehensive data governance framework that aligns with the EU General Data Protection Regulation and national laws. The framework aims to standardise consent procedures, data de‑identification protocols, and data sharing agreements across member states.
Capacity Building in Low‑Resource Settings
Recognising disparities in HTA capacity, the network plans to launch targeted training programmes for countries with emerging HTA infrastructures. These programmes will focus on building methodological expertise, establishing data systems, and creating national HTA agencies.
No comments yet. Be the first to comment!